- Home
- CRSP vs PAM Comparison
CRSP vs PAM Comparison
Compare CRSP & PAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- PAM
- Stock Information
- Founded
- CRSP 2013
- PAM 1945
- Country
- CRSP Switzerland
- PAM Argentina
- Employees
- CRSP N/A
- PAM N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- PAM Electric Utilities: Central
- Sector
- CRSP Health Care
- PAM Utilities
- Exchange
- CRSP Nasdaq
- PAM Nasdaq
- Market Cap
- CRSP 4.2B
- PAM 3.8B
- IPO Year
- CRSP 2016
- PAM N/A
- Fundamental
- Price
- CRSP $59.12
- PAM $70.82
- Analyst Decision
- CRSP Buy
- PAM Buy
- Analyst Count
- CRSP 16
- PAM 3
- Target Price
- CRSP $71.20
- PAM $85.83
- AVG Volume (30 Days)
- CRSP 3.5M
- PAM 169.0K
- Earning Date
- CRSP 08-04-2025
- PAM 08-06-2025
- Dividend Yield
- CRSP N/A
- PAM N/A
- EPS Growth
- CRSP N/A
- PAM 32.60
- EPS
- CRSP N/A
- PAM 0.41
- Revenue
- CRSP $37,675,000.00
- PAM $1,970,436,590.00
- Revenue This Year
- CRSP $30.25
- PAM $23.47
- Revenue Next Year
- CRSP $268.62
- PAM $22.99
- P/E Ratio
- CRSP N/A
- PAM $6.80
- Revenue Growth
- CRSP N/A
- PAM 21.62
- 52 Week Low
- CRSP $30.04
- PAM $38.58
- 52 Week High
- CRSP $63.68
- PAM $97.55
- Technical
- Relative Strength Index (RSI)
- CRSP 83.65
- PAM 50.26
- Support Level
- CRSP $50.26
- PAM $68.09
- Resistance Level
- CRSP $53.08
- PAM $75.40
- Average True Range (ATR)
- CRSP 2.78
- PAM 2.69
- MACD
- CRSP 0.93
- PAM 0.42
- Stochastic Oscillator
- CRSP 98.13
- PAM 69.53
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.